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Abstract
Background: Pregnancy is a period in the life of women that is often associated with decreased daily physical activity
and/or exercise. However, maintaining adequate levels of daily physical activity during pregnancy is important for mother
and child. Studies suggest that moderate daily physical activity and exercise during pregnancy are associated with
reductions in the risk of gestational diabetes mellitus (GDM). However, at present, physical activity is not routinely
advised to pregnant women at risk for gestational diabetes in the Netherlands. In FitFor2-study we aim to assess whether
an exercise program can improve insulin sensitivity and fasting plasma glucose levels of women at high risk for gestational
diabetes, assuming that this will lower their risk of gestational diabetes.
Methods: The FitFor2-study is a randomised controlled trial. Women who visit one of the participating hospitals or
midwifery practices and who are at risk for gestational diabetes are eligible to participate. After baseline measurement
they are randomly allocated to in the intervention or control group. The intervention group receives an exercise
program twice a week in addition to usual care. The exercise program consist of aerobic and strength exercises and
takes place under close supervision of a physiotherapist. Data are collected at 15, 24 and 32 weeks of pregnancy and 12
weeks after delivery. Primary maternal outcome measures are fasting plasma glucose and relative increase in insulin
resistance. Primary neonatal outcome is birth weight. Secondary outcome measures are: maternal serum triglycerides,
HDL, cholesterol, HbA1c, maternal weight gain during pregnancy, maternal physical activity level, foetal growth.
Discussion: If the FitFor2 intervention program proves to be effective, obstetricians and midwives should refer women
at risk for GDM to a special exercise program. Exercise programs for pregnant women under supervision of an
experienced trainer are already available in the Netherlands, and these programs could be adjusted easily for this target
group. Furthermore, the costs of these programs should be refunded by including them in the basic health care cost
reimbursement schemes.
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In 2007, the Centers for Disease Control and Prevention
(CDC) and the American College of Sports Medicine
(ACSM) have recommended that all healthy adults aged
18 to 65 yr accumulate moderate-intensity aerobic
(endurance) physical activity for a minimum of 30 min-
utes on five days each week or vigorous-intensity aerobic
physical activity for a minimum of 20 minutes on three
days each week. Combinations of moderate- and vigor-
ous-intensity activity can be performed to meet this rec-
ommendation [1]. Physical inactivity is a major risk factor
for cardiovascular and obesity-related diseases, such as
hypertension, atherosclerosis, and diabetes mellitus type
2 [2].
Pregnancy is a period in the life of women that is often
associated with decreased daily physical activity and
decreased participation in sports and exercise [3]. Ning et
al. reported that 23% of previously active women ceased
to engage in exercise completely during pregnancy [4].
Factors that might influence the level of physical activity
during pregnancy are, for instance, early pregnancy symp-
toms, such as nausea and fatigue or the perception that
physical activity during pregnancy is risky to maternal or
foetal health [3]. In the absence of either medical or
obstetric complications, the American College of Obstetri-
cians and Gynaecologists (ACOG) recommended 30 min-
utes or more of moderate exercise on most, if not all, days
of the week for pregnant women.
A reduction in daily physical activity levels and lack of
exercise is not the only change during pregnancy. Many
physiological changes occur: in body weight, the vascular
system, and in hormonal and energy balance. Shifts in
maternal metabolism result in an increased insulin resist-
ance during pregnancy. In women with a suboptimal
beta-cell function, the increase in insulin secretion may
not be sufficient to compensate the increased insulin
resistance, resulting in gestational diabetes mellitus
(GDM) [5]. GDM is defined as carbohydrate intolerance
of varying degrees of severity with onset or first recogni-
tion during pregnancy and disappearance after pregnancy.
GDM is associated with an increased maternal risk for
other pregnancy-related complications, such as pre-
eclampsia, postpartum haemorrhage, and with an
increased risk for developing type 2 diabetes after preg-
nancy [6]. It also puts the infant at risk, since gestational
diabetes is associated with an increased risk for macro-
somia, jaundice and birth trauma [6]. Later in life, chil-
dren of gestational diabetic mothers have an increased
risk for obesity, abnormal glucose tolerance, and type 2
diabetes [6].
In Western countries, the most common treatment for
women with GDM is dietary advice and secondly insulin
treatment. Although regular daily physical activity and/or
exercise is an established therapeutic adjunct in type 2 dia-
betes mellitus in non-pregnant adults, it is not routinely
offered to women with GDM. This is because physicians
and the mothers worry about several maternal physical
responses during exercises that may be negatively affect
the foetus [8]. Potential adverse effects could be growth
retardation, premature labour, foetal trauma [7]. How-
ever, no such ill-effects of moderate physical activity or
exercise have been found in the literature [7-10].
The importance of regular physical activity for glycaemic
control in women with GDM has already been shown
repeatedly. The increased insulin resistance normally
occurring during pregnancy can be reduced by increased
levels of moderate intensity daily physical activity [11,12].
Already in 1989, Jovanovic-Peterson et al. [13] showed in
a clinical trial that glycaemic control in women with GDM
was improved after treatment with an exercise program,
similar to improvements obtained with pharmacological
therapies. These results were confirmed later by others
[14-16]. However, most of these trials studied the effects
of a short term exercise program (i.e. a single bout or only
several weeks). Studies on longer lasting exercise pro-
grams, especially those continuing into the third trimester
of pregnancy, are currently lacking. Furthermore, most
studies concerned the treatment, and not the prevention
of GDM.
Only case-control and cohort studies are available as evi-
dence for a positive effect of regular physical activity and/
or exercise in the prevention of GDM [17-19]. However,
there are no reasons to suggest that the underlying mech-
anisms for GDM are any different than for type 2 diabetes
mellitus in non-pregnant individuals. Since daily physical
activity and/or exercise has been shown to be effective in
the prevention of type 2 diabetes in high-risk adults [20],
it is plausible that it will also be an effective strategy for
the prevention of GDM.
So, based on the literature, increasing levels of daily phys-
ical activity and/or participation in an exercise program
during pregnancy may be an effective strategy for the pre-
vention of GDM. However, at the moment, such a regime
is not routinely advised or prescribed for women at risk
for GDM in the Netherlands.
Consequently, in the FitFor2-study the effects of an exer-
cise program for women with an increased risk for GDM
on fasting blood glucose levels, insulin resistance, and
foetal birth weight in women with an increased risk for
GDM will be determined. The overall aim of the FitFor2
study is to assess whether an exercise program can
improve insulin sensitivity and fasting plasma glucose lev-
els of women at high risk for gestational diabetes, assum-Page 2 of 9
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objectives are a cost-effectiveness analysis and a process
evaluation (i.e. assessing the compliance with the exercise
program and what factors contribute to the success or fail-
ure of the program). The aim of this paper is to describe
the design of a randomised controlled trial, the FitFor2
study.
Methods
Study design
This study is designed as a randomised controlled trial
(RCT), to assess whether an exercise program improves
insulin sensitivity and fasting plasma glucose levels of
women at high risk for gestational diabetes, assuming that
this will lower their risk of GDM. The design is presented
in Figure 1. The Medical Ethics Committee of VU Univer-
sity Medical Centre at Amsterdam has approved the study
design, protocols, and informed consent procedure. All
participants must provide a written informed consent.
After baseline measurements, participants will be ran-
domly allocated to the control or intervention group. The
participants will be followed for 9 months: from 15 weeks
of pregnancy until 12 weeks after delivery.
Study population
Participants will be pregnant women at increased risk for
gestational diabetes. Women will be considered to be at
increased risk for GDM if they are obese (BMI ≥ 30) or
overweight (BMI ≥ 25) AND have at least one of the three
following characteristics [21,22]:
1) history of macrosomia (offspring with a birth weight
above the 97th percentile of gestational age);
Study designFigure 1
Study design.
Recruiting pregnant women at risk GDM
Checking eligibility criteria
Inclusion and informed consent
T0: baseline measurement (15 weeks of pregnancy)
Randomisation
Usual care (N=80)Exercising group and usual care (N=80)
Measurements: 24 and 32 weeks of pregnancyMeasurements: 24 and 32 weeks of pregnancy
Birth
Follow-up: 12 weeks post partum Follow-up: 12 weeks post partumPage 3 of 9
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pregnancy;
3) first grade relative with diabetes mellitus type 2.
Setting
This trial will be carried out in 10 midwifery practices and
3 larges hospitals in Amsterdam, The Netherlands. The
midwives and obstetricians working in these practices or
hospitals will invite women to participate in the study
from October 2007 until December 2009.
Inclusion and exclusion criteria
Pregnant women at increased risk for gestational diabetes
will be eligible to enter the study when they meet the fol-
lowing inclusion criteria: between 14 and 20 weeks of
pregnancy; over 18 years of age; sufficiently fluent in
Dutch; being able to be moderately physically active; and
willingness to give written informed consent.
Women will not be admitted to the RCT if they meet any
of the following exclusion criteria: diagnosed with (gesta-
tional) diabetes mellitus before randomisation; hyperten-
sion (systolic pressure > 160 mmHg and/or diastolic
pressure > 100 mmHg); alcohol abuse (i.e. 2 glasses alco-
hol or more per day); drug abuse (except for incidental
analgesic agents); use of the medication that affects insu-
lin secretion or insulin sensitivity (antiviral, corticoster-
oids, antihypertensive drugs, all concomitant medication
will be discussed); serious pulmonary (COPD, exercise-
induced asthma), cardiac, hepatic or renal (serum creati-
nine < 150 μmol/l) impairment; malignant disease; seri-
ous mental or physical impairment i.e. preventing to
understand or implement the study protocol/aim.
Recruitment
Women will be recruited at the Departments of Obstetrics
of VU University Medical Centre (VUMC), St. Lucas
Andreas Hospital (SLAZ) and Onze Lieve Vrouwe
Gasthuis (OLVG) in Amsterdam and 10 midwifery prac-
tices in Amsterdam. The obstetricians or midwives in the
3 hospitals and midwifery practices will introduce the
study at the first visit of every pregnant woman who is eli-
gible for inclusion. They will give the pregnant women
who are interested to participate a brochure about the
study to read at home. Obstetricians and midwives will
also fill out a reply coupon (name, telephone number,
inclusion and exclusion criteria) and will send this cou-
pon to the research team. Interested women can return the
informed consent form to the research team or the
research team calls within two weeks after receiving the
reply coupon. When women meet the inclusion criteria
and want to participate, they will be included. After inclu-
sion, an appointment for the baseline measurement will
be made.
Sample size
Power analysis is based on the effects of the intervention
program on fasting plasma glucose. A difference of 0.4
mmol/l in fasting plasma glucose between the two
research groups is considered to be clinically relevant.
Assuming a standard deviation of 0.7 mmol/l, this differ-
ence can be detected with a power (1-β) of 0.80 and an
alpha of 0.05 with two groups of 64 subjects. Taking a loss
to follow up of about 20% into account, a total of 160
subjects will be recruited. A significant difference of 300
grams in birth weight can also be detected with this
number of participants, assuming a standard deviation of
600 grams.
Randomisation
A computerized random number generator draws up an
allocation schedule pre-stratified for the hospital where
participants will be measured or where they will follow
the exercise program; within hospitals respondents will be
allocated at random to either the intervention or to the
control group. Block randomisation in blocks of four will
be performed. After baseline measurements, a research
assistant will inform the women about the group they will
be allocated to.
Blinding
The key of coding concerning group assignment will only
be known to the programmer of the database. The
researcher and research assistant will not be blinded for
allocation after randomisation. All outcome measures
will be assessed by independent examiners, unaware of
group allocation. Participants cannot be blinded for the
intervention, but will be asked not to reveal information
about their treatment to the examiners. Also obstetricians
and midwifes cannot be blinded for the allocated treat-
ment. Analyses will be performed blind for treatment allo-
cation.
Intervention
Intervention Group
Participants randomised to the intervention group will
complete an exercise program on two days of the week
during the remaining duration of the pregnancy. Each ses-
sion will last for 60 minutes. The exercise program will
consist of aerobic and strength exercises that will help to
control the blood glucose level. All sessions will be com-
pleted under the guidance and supervision of a specifi-
cally trained physiotherapist. The sessions will be located
at the Department Physiotherapy of the participating hos-
pitals (VUMC, OLVG and SLAZ).
At the first session the participants will be introduced to
the exercise program. They will be informed about the
structure of the sessions and will receive instructions in
the use of the equipment. Each exercise session will beginPage 4 of 9
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sity activity, such as slow cycling at a level of intensity of
50 Watt, that prepares the muscles for exercise. After the
warming-up, each participant completes an individual-
ised program of 40 minutes, consisting of 1 or 2 aerobic
exercises and 4 to 6 strength exercises. After exercising,
participants cool down for 5–10 minutes by slowly reduc-
ing the activity. This allows the heart rate to return to nor-
mal levels.
At the start of the intervention exercises will be adjusted to
maximal muscle strength and aerobic capacity of the
women. However, during pregnancy it is not possible to
determine maximal muscle strength and aerobic capacity
levels with standard physical tests because of the preg-
nancy related physiological changes. The one Repetition
Maximum (1-RM; the heaviest weight that can be lifted
only once) weight lifting test to measure muscular
strength cannot be used during pregnancy. Woman
should avoid overly vigorous activity, because most preg-
nant women have a decreased tolerance for weight-bear-
ing exercise and they should avoid the Valsalva maneuver
during resistance exercise [7,23]. Therefore 1RM for each
strength exercise will be predicted from the Oddvar
Holten diagram [24]. In short this prediction is done as
follows: the physiotherapist makes an estimation of the
weight that can be lifted for 10–20 times; the number of
repetitions that can be maximally performed is registered;
the percentage of intensity can than be looked up in the
Oddvar Holten diagram at the number of repetitions (fig-
ure 2) and 1RM can be computed by the formula (figure
3). For example, if a participant makes 16 repetitions with
24 kilos [i.e. 75% of 1 RM in the diagram] than, divide 24
by 0.75 for a 1RM of 32 kilos. To start an exercise program
for example at 30% of 1RM: multiply the 1RM by 30%; in
this case 32 times 0.30 equals 9.6 kilos. Consequently,
participants will start exercising at a training load of 30%
of 1RM with 15 repetitions, for 3 sets. Exercises will
progress by first increasing the number of repetitions
(from 15 to 30) and than by increasing the number of sets
of repetitions (from 3 to 5). The training load will be
increased (from 30 to 60% of 1RM) when the desired
number of (sets of) repetitions with the current load is
reached. For strength training, participants will use free
weights and different machines to target major muscle
groups in the upper body, thrunk and lower body.
ACSM recommends to not do a maximal aerobic exercise
test in nonclinical settings during pregnancy [25]. During
pregnancy maximal heart rate reserve decreases and rest-
ing heart rate increases. This makes the standard training
HR formulas ineffective [25]. ACOG and Canadian guide-
lines therefore recommend the use of ratings of perceived
exertion (RPE) in addition to heart rate [23,26]. Borg's
conventional 6–20-point scale is recommended, with 12
to 14 (a rating of 13 corresponds to a subjective rating of
"somewhat hard") identified as the RPE range to apply in
pregnancy [27,28]. The PARmed-X form pregnancy docu-
ment modified the target HR zones for exercise prescrip-
tion from the suggested target HR zones for nonpregnant
individuals. The target HR zone suggested for women
aged 20–29 yr is 135–150 bpm and for women aged 30–
39 yr 130–145 bpm [29]. These target HR zones during
pregnancy represent approximately 60–80% of aerobic
capacity based on age [23]. A check to avoid overexertion
will be the "talk test". The exercise intensity is too high if
the exercising pregnant woman is not able to carry on a
verbal conversation [23,29]. Aerobic training will be exe-
cuted on cycle ergometers, treadmills, cross-trainers, and
when still possible with the pregnant belly, on stationary
rowing machines. For every aerobic exercise a baseline
level of intensity will be estimated. This prediction will be
done as follows: for example a woman starts cycling at a
low work rate of 50 watt with a pedal rate at 50 rpm. The
physiotherapist increases the work load till an intensity is
Oddvar Holten diagramFigure 2
Oddvar Holten diagram.
% repetitions
100%  1 
95%  2 
90%  4 
85%  7 
80%  11 
75%  16 
70%  22 
65%  25 
Formulaigure 3
Formula. A: lifted weight; B: percentage of intensity.
A kg x 100% 
= 1 R.M. 
B % Page 5 of 9
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maintain cycling for 10 minutes on that intensity. Exer-
cises in the subsequent session will start on that baseline
intensity. When the RPE is rated under 12, the intensity
will be increased by increasing the working load. At each
training, attendance and the intensity of all strength and
aerobic exercises will be registered by the physiotherapist.
Training will take place under close supervision of a phys-
iotherapist. The physiotherapists will have expertise with
providing training for pregnant women. The physiothera-
pists will use the guide of the American College of Obste-
tricians and Gynaecologists [26,30] to maintain a safe and
healthy exercise program. Warning signs to terminate
exercise are; vaginal bleeding, dyspnoea before exertion,
dizziness, headache, chest pain, muscle weakness, calf
pain or swelling, preterm labour, decreased foetal move-
ment, amniotic fluid leakage [26]. Furthermore, during
training classes women will be encouraged to be physi-
cally active in their daily live also. Walking and cycling are
activities that can be maintained up until delivery, and
these are easily incorporated into daily live. To motivate
the women for daily physical activity, information on the
benefits for mother and child will be given at the start and
during the intervention. If indicated, women in the inter-
vention group will be treated as usual for GDM or other
complications during pregnancy.
Control group
The control group will receive usual care given by obstetri-
cians and midwives. Dutch midwives and obstetricians
follow closely the health status of each pregnant woman
and their unborn child. The first appointment is usually
between 9th and 12th week of gestation. For women who
develop GDM during the study, usual care consists of die-
tary advice and insulin treatment. Every treatment will be
registered in the medical records.
Non-participants
Women who decide not to participate after reading the
information brochure at home are asked to return a reply
coupon. They are asked to fill in weeks of pregnancy, body
weight, body height and reason for not participating.
Characteristics of this group will be compared to those
women who do participate in the study.
Outcome measurements
Participants in both intervention and control group are
invited for three measurement appointments during preg-
nancy and one appointment after pregnancy (see Table 1).
Outcome measurements are assessed at baseline (around
15 weeks of pregnancy), 24 and 32 weeks of pregnancy
and 12 weeks postpartum by means of physical measure-
ments, laboratory tests, and self-administered question-
naires.
Primary maternal outcome measures are fasting plasma glu-
cose and relative increase in insulin resistance. Primary
neonatal outcome is birth weight.
Secondary outcome measures are: maternal serum triglycer-
ides, HDL, cholesterol and HbA1c, maternal weight gain
during pregnancy, maternal physical activity level, foetal
growth. Changes in direct health care and non-health care
costs and indirect non-health care costs are studies as well.
Although the groups are too small to be able to detect sta-
tistically significant changes in these outcomes, the fol-
lowing variables will be assessed as well because of their
clinical importance: incidence of gestational diabetes,
macrosomia (97th percentile for gestational age), and
complications during pregnancy or delivery, such as
preeclampsia, caesarean section rate and need for labour
induction. These outcomes will be collected from the
medical records of the gynaecologist or midwife.
Data collection
Physical measurements
• Maternal anthropometric measures
Maternal body weight gain will be measured by calibrated
electronic scales (SECA 888) while participants are only
wearing indoor clothing. Body weight will be measured
twice, and the mean value of the two measurements will
be computed.
Maternal body height will be measured on bare feet by a
(wall mounted) height scale.
• Foetal and neonatal anthropometric measures
Foetal growth during the pregnancy will be measured by
ultrasound. Obstetrical ultrasound will be used to assess
Table 1: Schedule of measurements.
T0: 15 weeks pregnancy T1: 24 weeks pregnancy T2: 32 weeks pregnancy T3: 12 weeks post partum
Fasting blood sample OGTT* OGTT Fasting blood sample
Ultrasound* Ultrasound Neonatal weight**
Maternal weight Maternal weight Maternal weight Maternal weight
Accelerometer Accelerometer Accelerometer Accelerometer
Questionnaire Questionnaire Questionnaire Questionnaire
*measurement as part of usual care in hospital; **weight of the baby at delivery, as part of usual care.Page 6 of 9
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rapher of the hospital at 24 and 32 weeks of pregnancy.
Birth weight: At delivery, birth weight will routinely be
measured and recorded by the obstetrician, midwife or
the nurse. We will gather the birth weight from the medi-
cal records of the obstetrician of midwife.
• Physical activity
Physical activity will be measured by an accelerometer. At
15, 24 and 32 weeks of pregnancy and 12 weeks after
delivery an accelerometer will be sent to all participants.
They have to wear the accelerometer (Actitrainer) for 4
consecutive days to gather, objective data on the amount
of daily physical activity.
Questionnaire
• Physical activity will be assessed with the Activity Ques-
tionnaire for Adolescents & Adults (AQUA) [31].
• Quality of life will be assessed with the EuroQol [32,33].
• All costs related to pregnancy and delivery: direct health
care and non-health care costs and indirect non-health
care costs. Examples of direct health care costs are costs for
visits to the general practitioner, medical specialists, ther-
apists, dieticians, costs of medication and hospitalisation.
Examples of direct non-health care costs are the costs of
over-the-counter medication, travel time, and waiting
time. Indirect costs will include the costs of absence from
paid and unpaid work. Costs will be calculated by multi-
plying the volume of resource use by cost prices, following
the Dutch guidelines for economic evaluations in health
care to estimate costs [34].
• Potential confounding variables such as age, ethnicity,
socio-economic status, working status, and parity will be
measured also.
Laboratory tests
• Fasting blood samples
Fasting blood will be drawn from the antecubital vein
after a participant has fasted for at least 10 hours. From
this blood samples glucose, HbA1c, HDL-cholesterol, trig-
lycerides and cholesterol will be measured. HDL-choles-
terol, triglycerides and cholesterol will be measured by
means of enzymatic techniques (Boehringer-Mannheim,
Mannheim, Germany). HbA1c will be measured by High
Performance Liquid Chromatography. Plasma glucose
will be measured in plasma by means of a hexokinase-
method (Roche Diagnostics GmbH, Mannheim, Ger-
many).
• Oral Glucose Tolerance Test (OGTT)
An OGTT will be performed after a fasting period of at
least 10 hours. Blood samples will be collected in the fast-
ing state and 30, 60, 90, 120 and 180 minutes after inges-
tion of a glucose drink (100 g D-glucose in 0.5 l water).
Participants should not eat anything or do any physical
activity or exercise during the test. The insulin sensitivity
index will be calculated from a 100-g OGTT according to
the equation derived by Matsuda and DeFronzo [35] in
which insulin sensitivity is estimated by using the fasting
and mean glucose and insulin concentrations in serum
and HOMA-index. Simple fasting method to measure
insulin resistance is the homeostasis model assessment
(HOMA) (= fasting insulin concentration (μU/mL) × fast-
ing glucose concentration (mmol/L)/22.5)) [36].
Process evaluation
To assess factors that contribute to the success or failure of
the program, a process evaluation will be performed.
Trainers and a subgroup of 20 women will be interviewed
about their experiences with the exercise program. Attend-
ance to the exercise sessions will be recorded by the phys-
iotherapists. Furthermore, 10 women who have declined
to participate in the RCT will be interviewed about their
reasons for declining, and their possible barriers towards
participating in an exercise program.
Statistical analysis
Longitudinal, linear regression analyses will be per-
formed. In these analyses, the correlation between multi-
ple measurements within one individual is taken into
account. The regression coefficient reflects the average dif-
ference in the outcome variable between conditions. Pos-
sible confounders will be entered into the regression
analyses. Confounding will be defined as a change in the
regression coefficient of 10% or more. Possible effect
modification will be studied as well, defined as a signifi-
cant (p < 0.10) interaction-term between group allocation
and the variable concerned. Data will be analysed accord-
ing to the intention-to-treat principle.
Cost-utility analysis/Cost-effectiveness analysis
The cost-effectiveness analysis will consist of two compo-
nents. 1) A bootstrap technique will be used to estimate
the costs from a patient and health insurer's perspective.
2) A detailed cost-utility analysis, using a decision analytic
model will be performed to estimate costs associated with
primary and secondary outcomes. Ad 1) Differences in
mean costs between both groups will presented with 95%
confidence intervals estimated using bootstrapping meth-
ods [37]. Cost-effectiveness and cost-utility ratio's will be
assessed from a patient's and health insurer's perspective.
All direct and indirect costs will be taken into account.
Differences in direct, indirect and total costs between
groups will be computed with 95% confidence intervals
by using bootstrapping methods. Cost-effectiveness
planes and acceptability curves will be presented [38]. Ad
2) For the cost-utility analysis, a linear decision tree will
be modelled using the TreeAge Pro Healthcare Module.Page 7 of 9
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study will be supplemented by data from the literature.
The model will be build based on the same methodology
as described in the papers by Herbst [39] and Culligan
[40], in which decision analyses on macrosomia are dis-
cussed.
Discussion
The incidence of GDM is about 7% in the USA, but no
accurate data on the incidence in the Netherlands are
available. However, since the prevalence of overweight
and obesity is increasing strongly as a consequence, an
increase in the incidence of GDM is expected. Preventive
strategies for women at risk for GDM are therefore of great
importance. In the FitFor2-study, women with a high risk
of developing GDM are identified, and given an exercise
intervention, with the aim to prevent the occurrence of
GDM, and perhaps also diabetes in later life.
The prevention of GDM is also relevant for the children,
since it also puts the infant at risk. GDM is associated with
increased risk for macrosomia, jaundice and birth trauma.
Later in life, children of gestational diabetic mothers have
an increased risk for obesity, abnormal glucose tolerance,
and diabetes [6].
If the FitFor2 intervention program proves to be effective,
pregnant women will benefit from the exercise program
and a reduced risk for GDM. Obstetricians and midwives
should consequently refer women at risk for GDM to a
special exercise program. Implementation of the physical
activity program in the Netherlands is relatively easy,
since exercise programs for pregnant women under super-
vision of an experienced trainer are already available.
These programs may have to be adjusted slightly to the
FitFor2-program. Furthermore, the costs of these pro-
grams should be refunded by including them in the insur-
ance policies.
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